Standard BioTools (LAB) UBS Genomic Medicine Summit summary

Panel introductions and technology focus

• Leaders from diverse companies discussed advancements in spatial biology, proteomics, flow cytometry, and live tumor imaging.

• Technologies highlighted include spatial proteomics, full spectral profiling, advanced imaging for immunotherapy, and scalable platforms for clinical and research use.

• Emphasis on bridging research tools to clinical applications, especially in oncology and translational medicine.

Key technology trends and unmet needs

• High-plex and single-cell analysis are critical for discovery, while clinical adoption requires robust, standardized, and user-friendly platforms.

• Data analysis and interpretation remain major challenges due to the sheer volume and complexity of spatial and proteomic data.

• AI and deep learning are increasingly important for extracting insights from large imaging datasets.

• There is growing recognition in biopharma of the need for higher-plex data to improve clinical trial outcomes.

Market adoption and product cycles

• Spatial and omics technologies are in the early stages of adoption, with product cycles expected to last 10–15 years.

• Service-based models and leveraging existing instrument installed bases are seen as ways to accelerate clinical adoption.

• Collaborations with major players (e.g., Illumina) are expected to drive faster uptake and lower costs.